Finding the Right Course of Treatment for Parkinson's Disease

Published Online: Thursday, December 8, 2011
Follow Pharmacy_Times:
Pharmacy Times Office of Continuing Professional Education

The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson’s Disease

Jack J. Chen, PharmD, FCCP, BCPS, CGP
Associate Professor of Neurology, Department of Pharmacotherapy and Outcomes Science
Associate Professor, Department of Neurology, School of Medicine, Loma Linda University, Loma Linda, California

Michael W. Jann, PharmD
Professor and Chair, Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Mercer University, Atlanta, Georgia

Kelly E. Lyons, PhD
Research Professor of Neurology, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas

Rajesh Pahwa, MD
Laverne and Joyce Rider Professor of Neurology, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas

Parkinson’s disease (PD) is a progressive, disabling neurodegenerative characterized by bradykinesia and at least 1 of the following: resting tremor, muscle rigidity, and postural instability. This activity will focus on how Parkinson’s impacts patients, the therapeutic strategies often used, and the benefits of early diagnosis treatment. It includes 3 sections: “The Impact and Management of Nonmotor Symptoms of Parkinson’s Disease,” “Advanced Strategies for Treatment of Parkinson’s Disease: The Role of Early Treatment,” and “Implications for Managed Care for Improving Outcomes in Parkinson’s Disease: Balancing Aggressive Treatment with Appropriate Care.”

Educational Objectives
Upon completion of this educational activity, participants should be able to:
  • Describe the nonmotor symptoms involved in PD and their impact on patient quality of life.
  • Distinguish between the mechanisms of action of the major classes of pharmacotherapies used in the treatment of PD.
  • Evaluate therapeutic strategies employed in PD, and design individualized, specific therapeutic strategies based on varied patient characteristics.
  • Summarize the potential benefits of early PD diagnosis and treatment.
Credits: 3.0
Expiration Date: October 10, 2012

Click here to view this activity.
Related Articles
Sometimes, the pharmacist just can’t leave the counter. At certain locations, that dedication persists even after death, leading to tales of spectral pharmacists causing mischief and strange events at their former pharmacies.
B. Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association (NCPA), discusses increasing generic drug prices and the problems they create for independent community pharmacists.
Latest Issues